Literature DB >> 12532409

PDAPP; YFP double transgenic mice: a tool to study amyloid-beta associated changes in axonal, dendritic, and synaptic structures.

Robert P Brendza1, Cara O'Brien, Kelly Simmons, Daniel W McKeel, Kelly R Bales, Steven M Paul, John W Olney, Joshua R Sanes, David M Holtzman.   

Abstract

Neuritic plaques are one of the stereotypical hallmarks of Alzheimer's disease (AD) pathology. These structures are composed of extracellular accumulations of fibrillar forms of the amyloid-beta peptide (Abeta), a variety of other plaque-associated proteins, activated glial cells, and degenerating nerve processes. To study the neuritic toxicity of different structural forms of Abeta in the context of regional connectivity and the entire cell, we crossed PDAPP transgenic (Tg) mice, a model with AD-like pathology, to Tg mice that stably express yellow fluorescent protein (YFP) in a subset of neurons in the brain. In PDAPP; YFP double Tg mice, markedly enlarged YFP-labeled axonal and dendritic varicosities were associated with fibrillar Abeta deposits. These varicosities were absent in areas where there were nonfibrillar Abeta deposits. Interestingly, YFP-labeled varicosities revealed changes that corresponded with changes seen with electron microscopy and the de Olmos silver staining technique. Other silver staining methods and immunohistochemical localization of phosphorylated neurofilaments or phosphorylated tau were unable to detect the majority of these dystrophic neurites. Some but not all synaptic vesicle markers accumulated abnormally in YFP-labeled varicosities associated with neuritic plaques. In addition to the characterization of the effects of Abeta on axonal and dendritic structure, YFP-labeled neurons in Tg mice should prove to be a valuable tool to interpret the localization patterns of other markers and for future studies examining the dynamics of axons and dendrites in a variety of disease conditions in living tissue both in vitro and in vivo. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12532409     DOI: 10.1002/cne.10536

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  26 in total

1.  Loss of tau elicits axonal degeneration in a mouse model of Alzheimer's disease.

Authors:  H N Dawson; V Cantillana; M Jansen; H Wang; M P Vitek; D M Wilcock; J R Lynch; D T Laskowitz
Journal:  Neuroscience       Date:  2010-04-29       Impact factor: 3.590

2.  Two-photon microscopy for chemical neuroscience.

Authors:  Graham C R Ellis-Davies
Journal:  ACS Chem Neurosci       Date:  2011-04-20       Impact factor: 4.418

3.  In vivo characterization of a bigenic fluorescent mouse model of Alzheimer's disease with neurodegeneration.

Authors:  Sarah E Crowe; Graham C R Ellis-Davies
Journal:  J Comp Neurol       Date:  2013-07-01       Impact factor: 3.215

4.  White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network.

Authors:  Seonjoo Lee; Fawad Viqar; Molly E Zimmerman; Atul Narkhede; Giuseppe Tosto; Tammie L S Benzinger; Daniel S Marcus; Anne M Fagan; Alison Goate; Nick C Fox; Nigel J Cairns; David M Holtzman; Virginia Buckles; Bernardino Ghetti; Eric McDade; Ralph N Martins; Andrew J Saykin; Colin L Masters; John M Ringman; Natalie S Ryan; Stefan Förster; Christoph Laske; Peter R Schofield; Reisa A Sperling; Stephen Salloway; Stephen Correia; Clifford Jack; Michael Weiner; Randall J Bateman; John C Morris; Richard Mayeux; Adam M Brickman
Journal:  Ann Neurol       Date:  2016-04-27       Impact factor: 10.422

5.  Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice.

Authors:  Robert P Brendza; Brian J Bacskai; John R Cirrito; Kelly A Simmons; Jesse M Skoch; William E Klunk; Chester A Mathis; Kelly R Bales; Steven M Paul; Bradley T Hyman; David M Holtzman
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

6.  Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy.

Authors:  Tara L Spires; Melanie Meyer-Luehmann; Edward A Stern; Pamela J McLean; Jesse Skoch; Paul T Nguyen; Brian J Bacskai; Bradley T Hyman
Journal:  J Neurosci       Date:  2005-08-03       Impact factor: 6.167

7.  Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance.

Authors:  Thierry Bussière; Frédérique Bard; Robin Barbour; Henry Grajeda; Terry Guido; Karen Khan; Dale Schenk; Dora Games; Peter Seubert; Manuel Buttini
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

8.  Cholinergic forebrain degeneration in the APPswe/PS1DeltaE9 transgenic mouse.

Authors:  Sylvia E Perez; Saleem Dar; Milos D Ikonomovic; Steven T DeKosky; Elliott J Mufson
Journal:  Neurobiol Dis       Date:  2007-06-27       Impact factor: 5.996

9.  Diminished perisomatic GABAergic terminals on cortical neurons adjacent to amyloid plaques.

Authors:  Virginia Garcia-Marin; Lidia Blazquez-Llorca; José-Rodrigo Rodriguez; Susana Boluda; Gerard Muntane; Isidro Ferrer; Javier Defelipe
Journal:  Front Neuroanat       Date:  2009-11-20       Impact factor: 3.856

10.  Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575.

Authors:  Monica Garcia-Alloza; Meenakshi Subramanian; Diana Thyssen; Laura A Borrelli; Abdul Fauq; Pritam Das; Todd E Golde; Bradley T Hyman; Brian J Bacskai
Journal:  Mol Neurodegener       Date:  2009-05-06       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.